Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

SLU-PP-332 vs BPC-157 capsules: what the research compares

A side-by-side look at the published research on SLU-PP-332, a pan-ERR agonist, and BPC-157 capsules, covering what each is, what studies measured, and where the evidence is thin.

peptides-pro Editorial

SLU-PP-332 (also referred to as SLU-PP-332 ERRα/β/γ agonist) is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), a class of orphan nuclear receptors. The published literature characterises it as an exercise mimetic and a widely used chemical probe for ERR activation, with in vitro work describing its metabolism by human liver S9 fractions and its analytical detection by liquid chromatography–high resolution mass spectrometry [1][2]. BPC-157 is a synthetic pentadecapeptide derived from a fragment of human gastric juice protein; the evidence block provided for this comparison does not include sequence, formula, molecular weight, or receptor-family identifiers for BPC-157, and no published studies on BPC-157 capsules are supplied in the evidence block.

The work on SLU-PP-332 centres on the estrogen-related receptor (ERR) family of nuclear receptors, which regulate mitochondrial metabolism and exercise-responsive transcription [2].

Research Studies

SLU-PP-332 and ERR activation in cell-based functional assays

A comprehensive structure-activity relationship (SAR) analysis of the SLU-PP-332 scaffold integrated chemical synthesis, cell-based functional assays, downstream gene-expression profiling, and pharmacokinetic assessment. That work described SLU-PP-332 as a well-established exercise mimetic and widely used chemical probe for ERR activation, and noted that the structural features governing its potency, efficacy, selectivity, and drug-like properties had not been systematically elucidated prior to that analysis [2]. The same paper identified ERRs as master regulators of mitochondrial metabolism and exercise-responsive transcription [2].

SLU-PP-332 and in vitro metabolism in human liver S9 fractions

SLU-PP-332 and a related pan-ERR agonist, SLU-PP-915, were characterised using liquid chromatography–high resolution (tandem) mass spectrometry (LC-HRMS/MS). In vitro metabolic transformation products of both compounds were prepared using human liver S9 fractions. The authors framed this work around the compounds' ability to trigger human physiological processes similar to those initiated by physical activity, and around their potential relevance to sports drug testing programmes [1].

SLU-PP-332 and ERR targeting in myoblasts from inactive women

A pilot study enrolled twenty women undergoing hip arthroplasty for coxarthrosis, divided into an active group (n = 10) and an inactive group (n = 10) based on self-reported physical activity. The study aimed to evaluate ERR targeting in myoblasts isolated from the skeletal muscle of the inactive women by assessing metabolic and expression changes associated with ERR activation. The introduction to that paper noted that ERRs have been suggested as a potential therapeutic target to counteract muscle decline associated with aging or inactivity, and that they are known to regulate mitochondrial function and cellular respiration by up-regulating key factors in muscle responses to exercise [3].

SLU-PP-332 and doping-control analysis

A separate analysis and identification of in vitro metabolites of SLU-PP-332 was conducted for doping-control purposes. That work reported that exercise mimetics mimic physical activity and prevent development and progression of chronic metabolic diseases, including obesity and Type 2 diabetes, and that the World Anti-Doping Agency (WADA) prohibits the use of exercise mimetics and metabolic modulators in sports. SLU-PP-332 was described in that paper as a small, synthetic ERRα/β/γ agonist [4].

SLU-PP-332 and pharmacological activation of ERRα/β/γ as an exercise mimetic

A review examined pharmacological activation of ERRα/β/γ as an exercise mimetic and its potential therapeutic applications. The review noted that physical inactivity contributes to the development of chronic diseases, and that activation of the orphan nuclear receptors ERRα/β/γ has emerged as a molecular strategy to mimic exercise-induced benefits. Its stated aim was to systematically review the current evidence on the physiological, molecular, and clinical aspects of that approach [5].

SLU-PP-915 and aerobic exercise capacity

An orally active ERR agonist, SLU-PP-915, was reported to enhance aerobic exercise capacity. That paper described ERRα, ERRβ, and ERRγ as orphan nuclear receptors that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and the Krebs cycle, and stated that ERRs are essential for skeletal muscle adaptation to aerobic exercise and represent promising targets for therapeutic development [6].

SLU-PP-332 and metabolic syndrome

A study of a synthetic ERR agonist reported alleviation of metabolic syndrome. The paper noted that physical exercise induces physiologic adaptations and is effective at reducing the risk of premature death from all causes, and that pharmacological exercise mimetics may be effective in the treatment of a range of diseases including obesity and metabolic syndrome. It referenced the prior development of SLU-PP-332 as an ERR agonist [7].

BPC-157 capsules and the published record

The evidence block supplied for this comparison contains no studies of BPC-157 capsules. No sequence, formula, molecular weight, receptor family, tissue model, or measured outcome for BPC-157 is provided in the evidence block. As a result, no claim about BPC-157 capsules can be made here beyond noting the absence of supplied evidence.

Comparison table

Feature SLU-PP-332 BPC-157 capsules
Class Synthetic small-molecule pan-ERR agonist (ERRα/β/γ) [1][4] Not specified in the supplied evidence
Identifiers (sequence, formula, MW) Not provided in the supplied evidence Not provided in the supplied evidence
Pathway / receptor family Estrogen-related receptors (ERRα, ERRβ, ERRγ) [2][6] Not specified in the supplied evidence
In vitro metabolism Characterised using human liver S9 fractions and LC-HRMS/MS [1] Not reported in the supplied evidence
Cell-based functional assays Reported in SAR analysis of the scaffold [2] Not reported in the supplied evidence
Human tissue model Myoblasts from skeletal muscle of inactive women (pilot, n = 20 total) [3] Not reported in the supplied evidence
Doping-control relevance Discussed; WADA prohibits exercise mimetics and metabolic modulators [4] Not reported in the supplied evidence
Related compound data SLU-PP-915 reported to enhance aerobic exercise capacity in the cited paper [6] Not reported in the supplied evidence

Where the evidence is stronger

For SLU-PP-332, the supplied evidence includes in vitro metabolic characterisation in human liver S9 fractions [1], a structure-activity relationship analysis with cell-based functional assays and gene-expression profiling [2], a pilot study in myoblasts from inactive women [3], and review coverage of ERRα/β/γ activation as an exercise mimetic [5]. Related ERR agonist work includes a report on SLU-PP-915 and aerobic exercise capacity [6] and a study on a synthetic ERR agonist and metabolic syndrome [7].

For BPC-157 capsules, the supplied evidence contains no studies. The comparison therefore cannot be balanced on measured outcomes; the literature supplied here addresses only one of the two subjects.

What is not known

  • No sequence, molecular formula, or molecular weight for either compound is given in the supplied evidence.
  • No study of BPC-157 capsules is present in the supplied evidence, so no mechanism, tissue model, or measured outcome can be attributed to it here.
  • The pilot study in myoblasts from inactive women is described as a pilot and enrolled twenty women total; the supplied evidence does not report effect sizes or statistical outcomes [3].
  • The supplied evidence does not establish clinical efficacy for SLU-PP-332 in any population; the papers describe in vitro characterisation, SAR analysis, a pilot tissue study, and reviews [1][2][3][5].
  • No head-to-head study comparing SLU-PP-332 and BPC-157 capsules appears in the supplied evidence.

If you are reading this for personal health reasons

SLU-PP-332 is sold by our catalogue for laboratory research use only. We do not provide dosing or medical guidance, and nothing here is a recommendation for human use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp